Abacavir EP Impurity B with purity >98% in stock CAS 1443421-69-9 CAS NO.1443421-69-9

Topbatt Chemical Co. Ltd., Established in 2019, located in Shenzhen, Guangdong Province, is a Manufacturer and Trading company which specialized in fine chemicals like Pharmaceutical Reference Standards and Stable Isotopes. Our Stable Isotopes product line including 2H Labelled APIs, Reagents and Intermediates, 13C Labelled Substance, 15N Labelled Substance and 18O Labelled Substance.

We own a number of Senior pharmaceutical synthetic engineer, analysis engineer and analytical testing instrument. It make us have more than 1700 varieties compouds with high purity in stock in a short time.

We can provide you not only stock items, but also Custom Synthesis Service.

All of our products provided with COA, HPLC/GC, HNMR, qNMR, MS Spectrum.

After-sales issues will be settled in 24 hours.

Product Name: Abacavir EP Impurity B

Chemical Name: N6-cyclopropyl-9-((1R,4S)-4-((2,5-diamino-6-chloropyrimidin-4-yloxy)methyl)cyclopent-2-enyl)-9H-purine-2,6-diamine

Molecular Formula: C18H21ClN10O

Molecular Weight: 428.88

CAS#: 1443421-69-9

Purity: >98%

Price: Negotiable

Available Document: COA, HPLC/GC, HNMR, qNMR, MS Spectrum

Payment Term: Payment in advance by T/T.

Shipment: Package will dispatched in 7-15 days(According to the date of payment) by air.

Trade Term: EXW, FOB, CFR, DDU, DDP, ect.

Abacavir EP Impurity B is an impurity of Abacavir. Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Abacavir is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The concentration of drug necessary to effect viral replication by 50 percent (EC50) ranged from 3.7 to 5.8 μM (1 μM = 0.28 mcg/mL) and 0.07 to 1.0 μM against HIV-1IIIB and HIV-1BaL, respectively, and was 0.26 ± 0.18 μM against 8 clinical isolates. Abacavir had synergistic activity in cell culture in combination with the nucleoside reverse transcriptase inhibitor (NRTI) zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, and the protease inhibitor (PI) amprenavir; and additive activity in combination with the NRTIs didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and zalcitabine.